Author Question: The nurse admits a patient for treatment of cytomegalovirus (CMV). The patient has been ordered ... (Read 78 times)

Hungry! · **on:** Jul 23, 2018

The nurse admits a patient for treatment of cytomegalovirus (CMV). The patient has been ordered foscarnet (Foscavir), 40 mg/kg q812h given over 2 hours. By what route would the nurse administer this drug?

A) Sub q
B) IV
C) IM
D) PO

Question 2

The nurse is discharging a patient being sent home on antiemetic therapy. How would the nurse evaluate the plan of care that this patient has had while hospitalized?

A) Monitor for adverse effects.
B) Provide comfort and safety measures, including mouth care, ready access to bathroom facilities, assistance with ambulation and periodic orientation, ice chips to suck, protection from sun exposure, and remedial measures to treat dehydration if it occurs.
C) Assess the patient carefully for any potential drugdrug interactions.
D) Monitor laboratory test results including liver and kidney function tests.

batool · **Reply #1 on:** Jul 23, 2018

Answer to Question 1

B
Feedback:
Foscarnet is available in intravenous (IV) form only. It reaches peak levels at the end of the infusion and has a half-life of 4 hours. About 90 of foscarnet is excreted unchanged in the urine making it highly toxic to the kidneys. Use caution and at reduced dosage in patients with renal impairment. Options A, C, and D are incorrect.

Answer to Question 2

A
Feedback:
Monitor for adverse effects (dizziness, confusion, gastrointestinal alterations, cardiac arrhythmias, hypotension, gynecomastia, pink-to-brown-tinged urine, photosensitivity). The evaluation of the patient care plan would not include monitoring laboratory results (assessment phase), providing comfort measures, or assessing for drugdrug interactions (implementation phase).